
    
      The subjects who have been treated by resection due to hepatocellular carcinoma (HCC) will be
      randomized into 2 groups: the subjects in group A will be treated by Nucleotide analogues
      (NAs)( ETV, 0.5mg，qd；tenofovir disoproxil fumarate(TDF)，300mg，qd；ADV，10mg，qd）for 96 weeks;
      the subjects in group B will be treated by peginterferon alfa-2a （135μg/week）combination with
      NAs (ETV\TDF\ADV)for 96 weeks.
    
  